Price Chart

Profile

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
URL https://www.illumina.com
Investor Relations URL https://investor.illumina.com
HQ State/Province California
Sector Healthcare
Industry Diagnostics & Research
Equity Style Mid Cap/Value
Next Earnings Release Apr. 25, 2024 (est.)
Last Earnings Release Feb. 08, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
URL https://www.illumina.com
Investor Relations URL https://investor.illumina.com
HQ State/Province California
Sector Healthcare
Industry Diagnostics & Research
Equity Style Mid Cap/Value
Next Earnings Release Apr. 25, 2024 (est.)
Last Earnings Release Feb. 08, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A